Eledon Pharmaceuticals (ELDN) Total Current Liabilities (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Total Current Liabilities data on file, last reported at $13.5 million in Q1 2026.

• Quarterly Total Current Liabilities rose 46.52% year-over-year to $13.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.5 million (up 46.52% YoY) and the FY2025 annual result came in at $18.3 million, up 58.45% from the prior year.
• Total Current Liabilities fell to $13.5 million in Q1 2026, from $18.3 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $18.3 million in Q4 2025 to a low of $2.9 million in Q3 2023.
• A 5-year average of $8.2 million and a median of $6.3 million in 2022 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities slumped 53.84% — and 2024, when it surged 330.8%.
• Tracing ELDN's Total Current Liabilities over 5 years: stood at $6.5 million in 2022, then slumped by 39.85% to $3.9 million in 2023, then soared by 197.23% to $11.6 million in 2024, then soared by 58.45% to $18.3 million in 2025, then fell by 26.64% to $13.5 million in 2026.
• The last three Total Current Liabilities figures came in at $13.5 million (Q1 2026), $18.3 million (Q4 2025), and $14.3 million (Q3 2025), per Business Quant data.